Joint Formulary & PAD

Denosumab - Bone metastases from solid tumours

You are here : Home > Formulary Search > Denosumab - Bone metastases from solid tumours

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
Important

Biosimilar - prescribe by brand.

Documentation

Evidence Review
Denosumab - Bone Metastases from Solid Tumours - NICE TA265 - Oct 2012

PAD Profile

ChemicalSubstance :
Denosumab
Indication :
Bone metastases from solid tumours
Group Name :
Keywords :
Brand Names Include :
XGEVA
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

28 Nov 12 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

NICE guidance discussed at the PCN. Denosumab is not a payment by results excluded drugs and should be funded from within tariff by the oncology department within the acute trusts. See Surrey West Sussex & Hampshire cancer network protocol at the link below for more information St Luke's SACT Protocols and Policies | Royal Surrey NHS Foundation Trust

Other Indications

Below are listed other indications that Denosumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Bone metastases from solid tumours.

  • No records returned.